G3BP1 binds to guanine quadruplexes in mRNAs to modulate their stabilities.

Related articles

Tailored designs for RNA therapeutics

eBlogs

03
06
26

Manufacturing-informed design in therapeutic development  

Successful lab-in-the-loop approaches optimize RNA therapeutic design to be easily manufactured and produced.

read more

Grants

02
12
26

2026 mRNA Innovators Award Call for Applications

The mRNA Innovators Award offers matching funds to design and validate a therapeutic of interest using Eclipsebio's design models and characterization methods.

read more
Eclipsebio's closed-loop RNA drug discovery platform

eBlogs

02
07
26

The power of pairing RNA design and analytics 

Discover how closed-loop RNA development pairs design and sequencing to accelerate better therapeutics.

read more

Press Releases

01
26
26

Eclipsebio Acquires Terrain Bio to Expand Its End-to-End AI Platform for the Design, Manufacturing, and Validation of RNA Therapeutics

Originally posted on Business Wire SAN DIEGO, January 26, 2026 — Eclipse Bioinnovations, Inc. (Eclipsebio), the leader in sequencing-based analytics for RNA therapeutics, today announced the acquisition of Terrain Bio, a techbio company specializing in AI/ML RNA design and manufacturing analytics. The acquisition accelerates Eclipsebio’s strategy to deliver an integrated, data-first platform to support RNA […]

read more